Age-specific analysis of Trastuzumab Deruxtecan in HER2+ mBC.

A study analyzed the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC) patients of different age groups, using data from the DESTINY-Breast01, -02, and -03 trials, revealing valuable insights into T-DXd's use across varying ages.

0:05:46

5 months 28 Views

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/channel/OncologyConferences/videoEmbed/42077/trastuzumab-deruxtecan?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/channel/OncologyConferences/videoEmbed/42077/trastuzumab-deruxtecan?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/channel/OncologyConferences/videoEmbed/42077/trastuzumab-deruxtecan?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/channel/OncologyConferences/video/42077"><img src="https://oncologytubecom.cdn.ypt.me/view/img/video-placeholder-gray-portrait.webp?cache=1693571832_1693571832">Age-specific analysis of Trastuzumab Deruxtecan in HER2+ mBC.</a>

Link (BBCode):

[url=https://oncologytube.com/channel/OncologyConferences/video/42077][img]https://oncologytubecom.cdn.ypt.me/view/img/video-placeholder-gray-portrait.webp?cache=1693571832_1693571832[/img]Age-specific analysis of Trastuzumab Deruxtecan in HER2+ mBC.[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Breast

Description:

Ian Krop, MD, PhD - Yale University

This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (mBC) using data from the DESTINY-Breast01, -02, and -03 trials. The analysis aimed to evaluate the efficacy and safety of T-DXd across different age groups. The results provide valuable insights into the use of T-DXd in HER2-positive mBC patients of varying ages.